Investors and analysts had eagerly awaited this data as a test of Novo’s case that it has a strong pipeline of drugs to ...

Novo Nordisk NVO shares have plunged 17.9% in a week due to poorer-than-expected efficacy data from a late-stage study of its ...

Lilly and Novo still dominate the market for weight-loss and diabetes drugs, but the race is heating up in more ways than one ...

It’s not a new question, but it is one that is gaining increased traction: Is there a link between Novo Nordisk’s diabetes ...

Investors appeared disappointed by CagriSema’s Phase III readout, which showed weight loss that fell short of Novo Nordisk’s ...

Novo Nordisk has an opportunity to expand indications on its weight loss drugs. Check out on what could be next for NVO stock ...

As Novo Nordisk and Eli Lilly expand sales of their popular diabetes and weight-loss drugs, cheaper copies of their patented ...

Novo Nordisk's CagriSema Phase 3 data showed 22.7% weight loss, missing the company's own 25% target, causing a 20% drop in ...

Novo Nordisk posts disappointing update related to its new weight loss drug CagriSema. Novo Nordisk stock is now down 25% ...

As of 11:05 a.m. ET, Novo Nordisk stock is down a disheartening 20.8%, while both Lilly and Viking stocks are up 4.4% apiece.

Semaglutide use in diabetes patients is linked to a higher risk of NAION, a rare eye condition. A Danish-Norwegian study ...

Novo Nordisk shareholders were seeking on Friday to find out why such a high number of patients in the late-stage trial of ...